These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15302461)

  • 1. Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literature.
    Neuhouser ML; Kristal AR; Penson DF
    Urology; 2004 Aug; 64(2):201-11. PubMed ID: 15302461
    [No Abstract]   [Full Text] [Related]  

  • 2. [Polymorphisms of hormone-related genes and prostate cancer risk in Japan].
    Watanabe M; Hirokawa Y; Shiraishi T
    Nihon Rinsho; 2005 Feb; 63(2):219-24. PubMed ID: 15714969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.
    Madigan MP; Gao YT; Deng J; Pfeiffer RM; Chang BL; Zheng S; Meyers DA; Stanczyk FZ; Xu J; Hsing AW
    Int J Cancer; 2003 Nov; 107(2):271-5. PubMed ID: 12949806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prospects of genetic polymorphism analyses in prostatic disease].
    Kagawa S; Nishitani MA
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():474-8. PubMed ID: 12599622
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetic impact on prostate anatomical variability during ageing: role of CYP17, SRD5A2 and androgen receptor genes polymorphisms.
    Larré S; Hamadeh H; Azzouzi AR; Vallancien G; Cochand-Priollet B; Cancel-Tassin G; Cussenot O
    BJU Int; 2007 Sep; 100(3):679-84. PubMed ID: 17669147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanism of prostate cancer development].
    Tsuchiya N; Habuchi T
    Nihon Rinsho; 2005 Feb; 63(2):194-7. PubMed ID: 15714964
    [No Abstract]   [Full Text] [Related]  

  • 7. Genotyping of sex hormone-related pathways in benign and malignant human prostate tissues: data of a preliminary study.
    Balistreri CR; Caruso C; Carruba G; Miceli V; Candore G
    OMICS; 2011 Jun; 15(6):369-74. PubMed ID: 21348640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics of human androgens and prostatic diseases.
    Novelli G; Margiotti K; Sangiuolo F; Reichardt JK
    Pharmacogenomics; 2001 Feb; 2(1):65-72. PubMed ID: 11258198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
    Cicek MS; Conti DV; Curran A; Neville PJ; Paris PL; Casey G; Witte JS
    Prostate; 2004 Apr; 59(1):69-76. PubMed ID: 14991867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Genetic determinants of anatomical variants of the prostate].
    Hamadeh H; Larré S; Azzouzi AR; Cancel-Tassin G; Vallancien G; Cochand-Priollet B; Cussenot O
    Prog Urol; 2008 Apr; 18(4):214-22. PubMed ID: 18501301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphism and pathogenesis of benign prostatic hyperplasia.
    Konwar R; Chattopadhyay N; Bid HK
    BJU Int; 2008 Aug; 102(5):536-44. PubMed ID: 18410432
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular epidemiology of hormone-metabolic loci in prostate cancer.
    Makridakis NM; Reichardt JK
    Epidemiol Rev; 2001; 23(1):24-9. PubMed ID: 11588850
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog.
    Crescioli C; Ferruzzi P; Caporali A; Mancina R; Comerci A; Muratori M; Scaltriti M; Vannelli GB; Smiroldo S; Mariani R; Villari D; Bettuzzi S; Serio M; Adorini L; Maggi M
    Endocrinology; 2003 Jul; 144(7):3046-57. PubMed ID: 12810561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
    Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lifestyle factors and insulin-like growth factor 1 levels among elderly men.
    Signorello LB; Kuper H; Lagiou P; Wuu J; Mucci LA; Trichopoulos D; Adami HO
    Eur J Cancer Prev; 2000 Jun; 9(3):173-8. PubMed ID: 10954256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inherited variation in hormone-regulating genes and prostate cancer survival.
    Lindström S; Adami HO; Bälter KA; Xu J; Zheng SL; Stattin P; Grönberg H; Wiklund F
    Clin Cancer Res; 2007 Sep; 13(17):5156-61. PubMed ID: 17785571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of exercise and the risk of benign prostatic hyperplasia.
    Sea J; Poon KS; McVary KT
    Phys Sportsmed; 2009 Dec; 37(4):75-83. PubMed ID: 20048544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor GGC polymorphism and testosterone levels associated with high risk of prostate cancer and benign prostatic hyperplasia.
    Biolchi V; Silva Neto B; Pianta DB; Koff WJ; Berger M; Brum IS
    Mol Biol Rep; 2013 Mar; 40(3):2749-56. PubMed ID: 23184046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia.
    Tigli H; Yazici H; Dalay N
    Res Commun Mol Pathol Pharmacol; 2003; 113-114():307-14. PubMed ID: 15686129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
    Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ
    Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.